Citi analyst Yigal Nochomovitz raised the firm’s price target on Ideaya Biosciences to $29 from $26 and keeps a Buy rating on the shares. The analyst updated biotechnology models post the Q4 results.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on IDYA:
- Ideaya Buy thesis ‘remains intact’ after Q4 report, says Capital One
- Ideaya Biosciences reports Q4 EPS (50c), consensus (56c)
- IDEAYA Biosciences, Inc. Reports 2022 Financial Results and Provides Business Update
- Ideaya Biosciences initiated with an Outperform at RBC Capital
- Capital One more bullish on Ideaya Biosciences after study update